Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2)
A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
This PHASE2 trial investigates Mesothelioma and is currently completed. Intergroupe Francophone de Cancerologie Thoracique leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intergroupe Francophone de Cancerologie Thoracique
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Avignon, France , Clermont-Ferrand, France , Dijon, France , Grenoble, France , Le Havre, France , Le Mans, France , Lille, France , Marseille, France , Mulhouse, France and 11 more locations